Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Clinical trial NCT06786533 · RECRUITING

Trial details

NCT number: NCT06786533
Sponsor: Hemogenyx Pharmaceuticals LLC
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Start date: 2025-01-23
Primary completion: 2027-01-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.